Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-β-cyclodextrin

J. Blanchard, S. O. Ugwu, R. Bhardwaj, Robert T Dorr

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The objective of this study was to increase the solubility of phenytoin by complexing it with varying concentrations of 2-hydroxypropyl-β- cyclodextrin (HPBCD) and create an entirely aqueous formulation with a pH significantly closer to physiologic pH (7.4). The phenytoin-HPBCD complexation was characterized using phase-solubility analysis at HPBCD concentrations ranging from 10 to 50% w/v over the pH range of 7.4-11.0. The two most promising formulations, i.e., a formulation consisting of 40% HPBCD at pH 10.4, and a second formulation consisting of 20% HPBCD at pH 11.0, were selected for further study. Both formulations were entirely aqueous and had a significantly decreased pH compared to the original commercial formulation (Parke-Davis, pH 12.0). These formulations also exhibited a significantly decreased tendency to precipitate in vitro. The tissue irritation potential of the 20% w/v HPBCD formulation at pH 11.0 was found to be reduced considerably compared to the commercial injection in a BALB/c mouse model.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalPharmaceutical Development and Technology
Volume5
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Cyclodextrins
Phenytoin
Solubility
Injections

Keywords

  • 2-Hydroxypropyl-β-cyclodextrin
  • Complexation
  • In vitro precipitation
  • Phase solubility
  • Phenytoin
  • Skin toxicity

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-β-cyclodextrin. / Blanchard, J.; Ugwu, S. O.; Bhardwaj, R.; Dorr, Robert T.

In: Pharmaceutical Development and Technology, Vol. 5, No. 3, 2000, p. 333-338.

Research output: Contribution to journalArticle

@article{830b19ad0710478082f01c52404ab75d,
title = "Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-β-cyclodextrin",
abstract = "The objective of this study was to increase the solubility of phenytoin by complexing it with varying concentrations of 2-hydroxypropyl-β- cyclodextrin (HPBCD) and create an entirely aqueous formulation with a pH significantly closer to physiologic pH (7.4). The phenytoin-HPBCD complexation was characterized using phase-solubility analysis at HPBCD concentrations ranging from 10 to 50{\%} w/v over the pH range of 7.4-11.0. The two most promising formulations, i.e., a formulation consisting of 40{\%} HPBCD at pH 10.4, and a second formulation consisting of 20{\%} HPBCD at pH 11.0, were selected for further study. Both formulations were entirely aqueous and had a significantly decreased pH compared to the original commercial formulation (Parke-Davis, pH 12.0). These formulations also exhibited a significantly decreased tendency to precipitate in vitro. The tissue irritation potential of the 20{\%} w/v HPBCD formulation at pH 11.0 was found to be reduced considerably compared to the commercial injection in a BALB/c mouse model.",
keywords = "2-Hydroxypropyl-β-cyclodextrin, Complexation, In vitro precipitation, Phase solubility, Phenytoin, Skin toxicity",
author = "J. Blanchard and Ugwu, {S. O.} and R. Bhardwaj and Dorr, {Robert T}",
year = "2000",
doi = "10.1081/PDT-100100548",
language = "English (US)",
volume = "5",
pages = "333--338",
journal = "Pharmaceutical Development and Technology",
issn = "1083-7450",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-β-cyclodextrin

AU - Blanchard, J.

AU - Ugwu, S. O.

AU - Bhardwaj, R.

AU - Dorr, Robert T

PY - 2000

Y1 - 2000

N2 - The objective of this study was to increase the solubility of phenytoin by complexing it with varying concentrations of 2-hydroxypropyl-β- cyclodextrin (HPBCD) and create an entirely aqueous formulation with a pH significantly closer to physiologic pH (7.4). The phenytoin-HPBCD complexation was characterized using phase-solubility analysis at HPBCD concentrations ranging from 10 to 50% w/v over the pH range of 7.4-11.0. The two most promising formulations, i.e., a formulation consisting of 40% HPBCD at pH 10.4, and a second formulation consisting of 20% HPBCD at pH 11.0, were selected for further study. Both formulations were entirely aqueous and had a significantly decreased pH compared to the original commercial formulation (Parke-Davis, pH 12.0). These formulations also exhibited a significantly decreased tendency to precipitate in vitro. The tissue irritation potential of the 20% w/v HPBCD formulation at pH 11.0 was found to be reduced considerably compared to the commercial injection in a BALB/c mouse model.

AB - The objective of this study was to increase the solubility of phenytoin by complexing it with varying concentrations of 2-hydroxypropyl-β- cyclodextrin (HPBCD) and create an entirely aqueous formulation with a pH significantly closer to physiologic pH (7.4). The phenytoin-HPBCD complexation was characterized using phase-solubility analysis at HPBCD concentrations ranging from 10 to 50% w/v over the pH range of 7.4-11.0. The two most promising formulations, i.e., a formulation consisting of 40% HPBCD at pH 10.4, and a second formulation consisting of 20% HPBCD at pH 11.0, were selected for further study. Both formulations were entirely aqueous and had a significantly decreased pH compared to the original commercial formulation (Parke-Davis, pH 12.0). These formulations also exhibited a significantly decreased tendency to precipitate in vitro. The tissue irritation potential of the 20% w/v HPBCD formulation at pH 11.0 was found to be reduced considerably compared to the commercial injection in a BALB/c mouse model.

KW - 2-Hydroxypropyl-β-cyclodextrin

KW - Complexation

KW - In vitro precipitation

KW - Phase solubility

KW - Phenytoin

KW - Skin toxicity

UR - http://www.scopus.com/inward/record.url?scp=0033855301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033855301&partnerID=8YFLogxK

U2 - 10.1081/PDT-100100548

DO - 10.1081/PDT-100100548

M3 - Article

C2 - 10934732

AN - SCOPUS:0033855301

VL - 5

SP - 333

EP - 338

JO - Pharmaceutical Development and Technology

JF - Pharmaceutical Development and Technology

SN - 1083-7450

IS - 3

ER -